SLC6A14促进性结肠炎的进展,通过促进NLRP3炎症酶介导的热灭菌
Qing Gu1, Huan Xia2, Yue-Qiong Song1
1Department of Elderly Digestive, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology, Chengdu 610072, Sichuan Province, China.
World journal of gastroenterology
|February 5, 2024
概括
溶性载体家族6成员14 (SLC6A14) 通过调节NLRP3炎症酶,促进性结肠炎 (UC) 灭. 调节SLC6A14/NLRP3通路为UC提供了潜在的治疗策略.
科学领域:
- 胃肠病学 胃肠病学
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠病,其特点是经常复发.
- 驱动UC病变的精确分子机制,特别是溶液载体家族6成员14 (SLC6A14) 的作用,仍然不完全理解.
研究的目的:
- 为了研究SLC6A14在UC关联热的背景下的作用.
- 为了阐明SLC6A14和UC中的NLRP3炎症体之间的调节关系.
主要方法:
- 使用定量实时聚合酶连锁反应 (qRT-PCR),免疫染和免疫组织化学分析SLC6A14在人类UC组织中的表达.
- 使用细胞和动物模型,包括FHC和NCM460细胞的脂多糖 (LPS) 诱导的炎症,以及小鼠的硫酸 (DSS) 诱导的大肠炎.
- 使用ELISA,西部抹杀,qRT-PCR,EDU测定,CCK-8测定和流动细胞计量,量化了烧死标志物,细胞增殖和亡.
主要成果:
- 在UC组织中,SLC6A14表达显著升高,与NLRP3水平相关.
- 通过LPS刺激,肠道细胞系中SLC6A14的表达增加.
- 下调SLC6A14增强了细胞增殖,抑制了细胞灭亡,并减少了包括NLRP3.3在内的细胞灭亡标志物.
- 过度表达NLRP3部分逆转了SLC6A14对热的击倒作用.
- 在大肠炎的小鼠模型中,SLC6A14改善了粘膜损伤.
结论:
- 通过NLRP3炎症酶的调节,SLC6A14在促进UC热中起着至关重要的作用.
- 准SLC6A14/NLRP3轴为治疗性结肠炎提供了一个有前途的治疗途径.
更多相关视频
相关概念视频
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
186
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
186
01:29Drugs for Treatment of Ulcerative Colitis in IBD
141
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
141
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
430
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
430
01:22Pathophysiology of Peptic Ulcer Disease: Injurious Factors
592
Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
592
01:30Inflammatory Bowel Disease II: Crohn's Disease
244
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
244
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
334
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
334